Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform

by B2i | Sep 11, 2023 | Press Releases

ROCKVILLE, Md., Sept. 11, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...

Shuttle Pharma’s Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics

by B2i | Aug 29, 2023 | Press Releases

ROCKVILLE, Md., Aug. 29, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...

Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update

by B2i | Aug 15, 2023 | Press Releases

ROCKVILLE, Md., Aug. 15, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a...

Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates

by B2i | Aug 3, 2023 | Press Releases

ROCKVILLE, Md., March 22, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...

Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial

by B2i | Aug 3, 2023 | Press Releases

ROCKVILLE, Md., Aug. 3, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...